Clinical Trial Update: Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the effectiveness of Mirdametinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Mirdametinib (mirdametinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Status: RECRUITING